Merck's human papillomavirus vaccine has been approved for men in China, it said on Wednesday, providing the U.S. drugmaker a much-needed boost in a key market where demand has been falling among women.

China’s drug regulator approved Merck & Co.’s blockbuster HPV vaccine for use by men, opening a new untapped market for the US drug giant after a rush among women to get the shot lost steam.

Merck's Gardasil vaccine, previously only available to women, has now been approved for men in China. This approval may help Merck overcome declining sales due to weak demand among women and disruptions caused by China's anti-corruption campaign.

U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's medical products administration, providing a much-needed boost to the company in a key market.

The HPV vaccine, Gardasil, has gained approval for additional indications from China's National Medical Products Administration, becoming the first and only HPV vaccine authorized for use in men in China,

GARDASIL is the first HPV vaccine approved for the prevention of certain HPV-related cancers and diseases in Chinese males

The recipient in Changsha, the capital of Hunan province, became the first man on the Chinese mainland to receive the HPV vaccine, after US pharmaceutical giant Merck announced its quadrivalent HPV vaccine Gardasil had been approved for additional indications by the National Medical Products Administration.

Merck & Co's human papillomavirus (HPV) vaccine, Gardasil, has received approval from China's medical products administration for men aged 9-26 years.Gardasil, a key product for Merck alongside